Physician
Bay Area Hospital District
Bay Area Hospital District was paid $8.70M by Medicaid between Jan 2018 and Dec 2024, across 185 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoBAY AREA HOSPITAL DISTRICT
COOS BAY, OR 97420
COOS BAY, OR 97420
33aNPI1225016561assigned 01/06/2006
33bProvider typeAnesthesiology Physician
28Total paid$8.70M
24GClaims475,130
24DCodes billed185
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anesthesiology Physician providers in Oregon
Rank by total paid#8 of 43
Median peer was paid$94K
This provider vs. median93×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68,965 | $778K | |
| 2019 | 71,679 | $863K | |
| 2020 | 53,546 | $601K | |
| 2021 | 63,236 | $715K | |
| 2022 | 69,634 | $727K | |
| 2023 | 79,294 | $1.70M | |
| 2024incomplete | 68,776 | $3.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 38,046 | 33,819 | $2.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 26,512 | 22,432 | $2.09M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.2% | 2,613 | 2,272 | $626K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.4% | 32,316 | 18,844 | $470K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4.7% | 6,413 | 4,760 | $408K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 10,609 | 9,017 | $397K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.3% | 7,168 | 5,530 | $289K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 7,115 | 6,363 | $271K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 2,896 | 2,479 | $218K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.8% | 7,480 | 4,084 | $153K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1.7% | 32,653 | 23,971 | $148K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.6% | 3,229 | 3,058 | $139K |
173 more codes
| 71045 | Radiologic examination, chest; single view | 1.5% | 11,418 | $133K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.4% | 3,477 | $119K |
| 59025 | Fetal non-stress test | 1.1% | 1,270 | $92K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,378 | $85K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,464 | $83K |
| 97602 | <1% | 2,272 | $65K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 1,380 | $64K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,171 | $51K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,593 | $44K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,917 | $40K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,056 | $37K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 823 | $31K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 441 | $29K |
| 76830 | Ultrasound, transvaginal | <1% | 697 | $26K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,335 | $25K |
| 97597 | <1% | 1,441 | $24K | |
| 80053 | Comprehensive metabolic panel | <1% | 45,388 | $19K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 686 | $19K |
| 76642 | <1% | 611 | $19K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,809 | $18K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,556 | $18K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,645 | $17K |
| 93798 | <1% | 612 | $14K | |
| 0011A | <1% | 519 | $11K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,087 | $11K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,131 | $11K |
| 77066 | Tomosynthesis, mammo | <1% | 267 | $10K |
| 86900 | <1% | 180 | $9K | |
| 29581 | <1% | 128 | $9K | |
| 0012A | <1% | 389 | $9K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,876 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,324 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 31,706 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 48,117 | $6K |
| 71271 | <1% | 121 | $5K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 16 | $5K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 157 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,000 | $4K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 78 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,135 | $4K |
| 93298 | <1% | 193 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 180 | $3K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 128 | $3K |
| 86780 | <1% | 538 | $3K | |
| 80061 | Lipid panel | <1% | 457 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 101 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 69 | $3K |
| 83970 | <1% | 789 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,283 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 52 | $2K |
| 77065 | Tomosynthesis, mammo | <1% | 75 | $2K |
| 96415 | <1% | 69 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 54 | $2K |
| 93248 | <1% | 96 | $2K | |
| 97802 | <1% | 13 | $1K | |
| 93296 | <1% | 516 | $1K | |
| 87070 | <1% | 251 | $1K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 32 | $1K |
| 84481 | <1% | 700 | $1K | |
| 99223 | Prolong inpt eval add15 m | <1% | 16 | $1K |
| 96367 | <1% | 126 | $1K | |
| 84425 | <1% | 110 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 211 | $1K |
| 83735 | <1% | 4,897 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 16 | $965.41 |
| 83615 | <1% | 7,619 | $947.31 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 325 | $917.24 |
| 93016 | <1% | 81 | $909.41 | |
| 82728 | <1% | 429 | $901.05 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 84 | $878.51 |
| 93295 | <1% | 92 | $795.83 | |
| 93294 | <1% | 125 | $751.73 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,804 | $729.25 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 30 | $699.02 |
| 99460 | <1% | 16 | $696.96 | |
| 84480 | <1% | 79 | $644.89 | |
| 87631 | <1% | 306 | $621.89 | |
| 93018 | <1% | 81 | $606.41 | |
| 86762 | <1% | 63 | $576.33 | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $572.48 |
| 93308 | <1% | 13 | $540.11 | |
| A9270 | Non-covered item or service | <1% | 3,612 | $512.49 |
| 93971 | <1% | 27 | $470.85 | |
| 84100 | <1% | 1,480 | $441.19 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 192 | $430.38 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 91 | $399.68 |
| 86803 | <1% | 88 | $399.63 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 50 | $396.03 |
| 87340 | <1% | 149 | $391.11 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 104 | $381.75 |
| 76536 | <1% | 16 | $346.70 | |
| 81001 | <1% | 15,136 | $346.16 | |
| 82570 | <1% | 703 | $325.72 | |
| 80177 | <1% | 101 | $321.41 | |
| 81025 | <1% | 2,960 | $309.33 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 84 | $299.27 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $283.99 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 14 | $283.00 |
| 82607 | <1% | 104 | $268.68 | |
| 86481 | <1% | 15 | $249.20 | |
| 87428 | <1% | 49 | $248.85 | |
| 84156 | <1% | 714 | $231.07 | |
| 84403 | <1% | 12 | $197.23 | |
| 84402 | <1% | 12 | $194.62 | |
| 73030 | <1% | 20 | $193.02 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 366 | $191.95 |
| 83880 | <1% | 1,741 | $146.76 | |
| 83655 | <1% | 14 | $123.54 | |
| 82378 | <1% | 231 | $109.37 | |
| 86706 | <1% | 32 | $105.44 | |
| 84484 | <1% | 9,001 | $94.13 | |
| 86850 | <1% | 182 | $85.93 | |
| 73562 | <1% | 14 | $80.51 | |
| 82533 | <1% | 44 | $79.20 | |
| 83690 | <1% | 4,444 | $67.58 | |
| 99152 | <1% | 19 | $46.78 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 21 | $44.03 |
| 84439 | <1% | 38 | $43.86 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 238 | $41.44 |
| 85027 | <1% | 102 | $39.05 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 77 | $37.56 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,281 | $36.63 |
| 86901 | <1% | 180 | $29.26 | |
| 86300 | <1% | 240 | $17.12 | |
| 87430 | <1% | 12 | $16.81 | |
| 83605 | <1% | 929 | $9.76 | |
| 86704 | <1% | 16 | $8.44 | |
| 85007 | <1% | 21 | $5.92 | |
| 81003 | <1% | 2,352 | $1.58 | |
| 85610 | <1% | 723 | $1.40 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,776 | $0.75 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 427 | $0.69 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 14 | $0.32 |
| 87040 | <1% | 70 | $0.20 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 3,172 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 314 | $0.00 |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 412 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 57 | $0.00 |
| 82077 | 0% | 152 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 654 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 619 | $0.00 |
| 85730 | 0% | 71 | $0.00 | |
| 87077 | 0% | 87 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 76 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 26 | $0.00 |
| 87088 | 0% | 13 | $0.00 | |
| 80050 | General health panel | 0% | 32 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 14 | $0.00 |
| 96376 | 0% | 12 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 37 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 29 | $0.00 |
| 36591 | 0% | 47 | $0.00 | |
| 99024 | 0% | 14 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 14 | $0.00 |
| 86695 | 0% | 16 | $0.00 | |
| 87522 | Neg quan hep c or qual rna | 0% | 16 | $0.00 |
| 86708 | 0% | 16 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 3,943 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 2,521 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 354 | $0.00 |
| 90715 | 0% | 13 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 464 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 366 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 59 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 154 | $0.00 |
| 84702 | 0% | 16 | $0.00 | |
| 87186 | 0% | 14 | $0.00 | |
| 86696 | 0% | 16 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 14 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 47 | $0.00 |
| 84145 | 0% | 15 | $0.00 | |
| 86709 | 0% | 16 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOORE, BRIAN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Moore Counseling & Mediation Services, INC. | Euclid, OH | $9.18M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.